Arxis director buys 25,000 shares at $28

Arxis, Inc. director Stephen Duane Oetgen reported new investments in the company’s Class A Common Stock.

Rhea-AI Filing Summary

Arxis, Inc. director Stephen Duane Oetgen reported new investments in the company’s Class A Common Stock. He made an open-market purchase of 25,000 shares at $28.00 per share, and after this trade he directly holds 30,357 shares.

Separately, he received a grant of 5,357 restricted stock units, which will vest on the first anniversary of the grant date. The purchased shares were acquired through the directed share program conducted in connection with Arxis’s initial public offering.

Insider Trade Summary

Net Buyer: 25,000 shares

Net Buy 2 txns

Insider Oetgen Stephen Duane

Role Director

Bought 25,000 shs ($700K)

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	5,357	$0.00	$0.00
Purchase	Class A Common Stock	25,000	$28.00	$700K

Holdings After Transaction: Class A Common Stock — 30,357 shares (Direct)

Footnotes (2)

1. F1. Represents an award of restricted stock units with respect to Class A Common Stock which will vest on the first anniversary of the grant date.
2. F2. Represents shares of Class A Common Stock purchased by the Reporting Person through the directed share program conducted in connection with the Issuer's initial public offering.

Key Figures

Open-market purchase: 25,000 shares Purchase price: $28.00 per share Shares held after purchase: 30,357 shares +2 more

5 metrics

Open-market purchase 25,000 shares Class A Common Stock bought on 2026-04-17

Purchase price $28.00 per share Open-market transaction on 2026-04-17

Shares held after purchase 30,357 shares Direct Class A Common Stock ownership after trade

RSU grant size 5,357 units Restricted stock units vesting on first anniversary

Net buy shares 25,000 shares Net buy direction for this Form 4

Key Terms

restricted stock units, directed share program, initial public offering

3 terms

restricted stock units financial

"Represents an award of restricted stock units with respect to Class A Common Stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

directed share program financial

"purchased by the Reporting Person through the directed share program"

initial public offering financial

"directed share program conducted in connection with the Issuer's initial public offering"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Arxis (ARXS) director Stephen Duane Oetgen report?

Stephen Duane Oetgen reported buying 25,000 shares of Arxis Class A Common Stock and receiving 5,357 restricted stock units. The filing reflects both an open-market purchase and an equity award granted as compensation.

At what price did the Arxis (ARXS) director buy shares in this Form 4?

The director purchased 25,000 shares of Arxis Class A Common Stock at $28.00 per share. This open-market transaction was made through the issuer’s directed share program associated with its initial public offering.

How many Arxis (ARXS) shares does the director hold after the reported purchase?

After the open-market purchase, the director directly holds 30,357 shares of Arxis Class A Common Stock. This figure reflects his direct ownership position immediately following the 25,000-share acquisition.

What are the terms of the 5,357 restricted stock units reported for Arxis (ARXS)?

The director received 5,357 restricted stock units tied to Arxis Class A Common Stock. These RSUs will vest in full on the first anniversary of the grant date, subject to the applicable vesting conditions.

Was the Arxis (ARXS) share purchase part of the company’s IPO directed share program?

Yes. The filing states the 25,000 shares were purchased through the directed share program conducted in connection with Arxis’s initial public offering, indicating participation in that specific IPO-related allocation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/20/2026 - 09:07 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oetgen Stephen Duane

(Last) (First) (Middle)

1332 BLUE HILLS AVENUE

(Street)

BLOOMFIELD CONNECTICUT 06002

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arxis, Inc. [ ARXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	04/17/2026		A		5,357(1)	A	$0	5,357	D
Class A Common Stock	04/17/2026		P		25,000(2)	A	$28	30,357	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units with respect to Class A Common Stock which will vest on the first anniversary of the grant date.

2. Represents shares of Class A Common Stock purchased by the Reporting Person through the directed share program conducted in connection with the Issuer's initial public offering.

	/s/ Jennifer Allen, attorney-in-fact for Stephen Oetgen	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)